FY2025 Earnings Forecast for Medpace Issued By William Blair

Medpace Holdings, Inc. (NASDAQ:MEDP) – Stock analysts at William Blair lifted their FY2025 earnings per share (EPS) estimates for shares of Medpace in a research report issued to clients and investors on Thursday, October 23rd. William Blair analyst M. Smock now forecasts that the company will post earnings of $14.77 per share for the year, up from their previous forecast of $14.16. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $4.15 EPS, Q1 2026 earnings at $3.90 EPS, Q2 2026 earnings at $4.36 EPS and Q4 2026 earnings at $4.34 EPS.

MEDP has been the subject of several other reports. Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 22nd. Barclays upped their target price on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research report on Friday. Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday. Finally, Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and upped their target price for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $464.00.

Medpace Price Performance

MEDP opened at $605.20 on Monday. The business has a fifty day simple moving average of $503.13 and a 200 day simple moving average of $392.69. The company has a market capitalization of $17.05 billion, a PE ratio of 42.32, a price-to-earnings-growth ratio of 3.58 and a beta of 1.40. Medpace has a 1 year low of $250.05 and a 1 year high of $625.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS.

Institutional Trading of Medpace

Several institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its position in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Wasatch Advisors LP increased its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in Medpace by 17.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares in the last quarter. AQR Capital Management LLC increased its holdings in Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after purchasing an additional 81,637 shares in the last quarter. Finally, TD Asset Management Inc increased its holdings in Medpace by 15.6% in the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after purchasing an additional 61,764 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 36,196 shares of the company’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,478 shares of company stock worth $23,093,073 in the last ninety days. 20.30% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.